about
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNSSmall GSK-3 Inhibitor Shows Efficacy in a Motor Neuron Disease Murine Model Modulating AutophagySynthesis, Structural Analysis, and Biological Evaluation of Thioxoquinazoline Derivatives as Phosphodiesterase 7 InhibitorsNovel potential agents for human cytomegalovirus infection: synthesis and antiviral activity evaluation of benzothiadiazine dioxide acyclonucleosidesPDE 7 inhibitors: new potential drugs for the therapy of spinal cord injuryPhosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson diseaseProtein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis.Good oral absorption prediction on non-nucleoside benzothiadiazine dioxide human cytomegalovirus inhibitors using combined chromatographic and neuronal network techniques.Nonnucleoside human cytomegalovirus inhibitors: synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives.Benzyl derivatives of 2,1,3-benzo- and benzothieno[3,2-a]thiadiazine 2,2-dioxides: first phosphodiesterase 7 inhibitors.N-Benzylpiperidine derivatives of 1,2,4-thiadiazolidinone as new acetylcholinesterase inhibitors.Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching.Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseasesGlycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease.Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice.Enantioselective LC/MS method for the determination of an antimalarial agent Fenozan B07 in dog plasma.An application of two MIFs-based tools (Volsurf+ and Pentacle) to binary QSAR: the case of a palinurin-related data set of non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors.Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities.A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation.Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases.Recent strategies in the development of new human cytomegalovirus inhibitors.Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson diseaseGlycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation.Non-cholinergic pharmacotherapy approaches to the future treatment of Alzheimer's disease.Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease.CB1 blockade potentiates down-regulation of lipogenic gene expression in perirenal adipose tissue in high carbohydrate diet-induced obesityImpairments in cognition and neural precursor cell proliferation in mice expressing constitutively active glycogen synthase kinase-3.AMPA glutamate receptors and neuropathic pain.Reduction of body weight, liver steatosis and expression of stearoyl-CoA desaturase 1 by the isoflavone daidzein in diet-induced obesity.Phosphodiesterase 7 inhibition induces dopaminergic neurogenesis in hemiparkinsonian rats.GSK-3 inhibitors: discoveries and developments.Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3β Inhibitors.Novel Triazole-Quinoline Derivatives as Selective Dual Binding Site Acetylcholinesterase Inhibitors.Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosisSmall molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosa.Interference of the complex between NCS-1 and Ric8a with phenothiazines regulates synaptic function and is an approach for fragile X syndrome.Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice.Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.
P50
Q21129334-79DF23D0-E736-4E97-BC9B-7B63B5340C7CQ27322519-9738479F-E94A-4458-BCA1-20C1C947BAD2Q27654567-5D98DFAF-EBFE-4B79-AFB3-1BD039005F33Q28373304-ED704169-3F89-4AE7-82FA-A0510B2EC18AQ28477025-84861149-F297-4BEA-9BA9-CE7CC463BD24Q28742424-D0C7FA5E-8884-4D27-BF7C-518B28177B67Q30574827-DDE6462E-0A21-4C27-9282-D2ACE47F09EBQ30848112-8F4BA247-8327-4CF9-BD37-A927D46C573AQ31433791-1BE5728B-434B-4FED-B524-77B9FBA15AC4Q31536770-2FF9C748-B88C-406C-96C7-7AD3C70B1378Q31836439-767B5F42-0AD7-4429-B92B-8AB66C96C121Q33193966-73C537EC-E6B6-426A-9F3C-212D3065AC13Q33251948-651346FD-3A91-4630-B437-F804A4888CAAQ33294648-2F7FCEC4-A420-4F9A-A7E8-11A5EF181165Q33353843-000C8329-F636-47AD-85D4-8E17081EB815Q33434906-E9FD4B70-13F7-422E-96C9-E5AC87AA2CE0Q33808066-4F486B2C-ACB1-423C-9AA6-A713B5308836Q34066033-920C1C1B-230F-4904-A94E-7B4C0DD20BE2Q34114869-0ADF6934-6039-4D2A-A549-17813A79FF38Q34122676-CEEE1735-6ECE-4936-AEB5-7503E63D5AAAQ34218241-F7EF53E2-56D0-4CC0-A15D-EA91026EC9D4Q34234232-3402E29A-DACC-44BF-B4A0-6B89AC96E58BQ34591684-7491DBA2-3F7E-4570-9780-2242A56757ABQ34732988-BAAEC441-B0CA-4264-9D56-885B4C194C0DQ34947295-FE5F7B8A-309F-46B1-8115-526B1EF2F9F9Q34947564-87EE213A-D362-4E66-BE64-2AFDDD63489DQ35108574-28CF3036-7004-40E0-BEDA-068AD4329807Q35146005-A6C20A42-3D6D-495C-B02B-CE82312205ACQ35552192-73002FC2-EE12-4049-B531-25BB214A46E0Q35636132-53C00590-B4D8-4814-B54C-83E87B3C6E82Q35665339-BEA98991-63CD-43DC-B7D1-6D32C6630D96Q35699636-05170894-6D2A-4276-92BD-2C3BC4EA12A3Q35876179-E716A363-0F08-48A8-8C14-104E10998283Q35918929-0C2705A6-F8FA-4586-B0D8-F325C82564D1Q35933128-93E24DF1-4C42-45C2-AF18-502311164A67Q36016406-66BCB05C-ECCC-4F98-96E5-968C0E811625Q36257802-CE8DD2C5-533D-4B3F-80D7-0A731B3F5DE9Q36259253-A089372C-F72C-4266-AD4E-CFD8F15B0FD9Q36326799-E2ABEE23-BFCB-4FFB-978D-39491C8D69F7Q36349629-C629E355-7F14-40A6-9BDE-811803DD4967
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Ana Martinez
@ast
Ana Martinez
@en
Ana Martinez
@es
Ana Martinez
@fr
Ana Martinez
@nl
Ana Martinez
@sl
type
label
Ana Martinez
@ast
Ana Martinez
@en
Ana Martinez
@es
Ana Martinez
@fr
Ana Martinez
@nl
Ana Martinez
@sl
prefLabel
Ana Martinez
@ast
Ana Martinez
@en
Ana Martinez
@es
Ana Martinez
@fr
Ana Martinez
@nl
Ana Martinez
@sl
P1015
P214
P227
P244
P269
P1015
P1053
L-6414-2014
P106
P1153
7404025454
P1207
n2011212581
P21
P213
0000 0001 1499 5190
P214
P227
P244
n2006016642
P269
P31
P3829
P496
0000-0002-2707-8110
P5361
MartínezAna1961-